ARIA Stock UPDATES Ariad Pharmaceuticals (ARIA) 5.89 09/17/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 17, 2014 at 1:59 PM

Ariad Pharmaceuticals (ARIA) 5.89 $ARIA

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US

Why Ariad Pharmaceuticals, Inc. Stock Plunged 11% in 2014
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 08, 1:10PM CDT
All things considered, it's been a relatively calm year for Ariad Pharmaceuticals shareholders after their stock went cliff-diving in October of last year. With its shares down 11% year-to-date stakeholders probably aren't happy, but compared to...

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.

Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:

'Mad Money' Lightning Round: Yahoo! Is One of the Best Buys Around
at The Street - Thu Sep 04, 5:00AM CDT
Cramer likes Araid Pharmaceuticals and Occidental Petroleum and is sticking with his Taser recommendation.

Jim Cramer's 'Mad Money' Recap: These Are 3 Stocks Cramer Trusts
at The Street - Wed Sep 03, 7:17PM CDT
Cramer wants Apple, Microsoft and Dow Chemical on his team.

Ariad Pharmaceuticals Rises 4.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Aug 26, 4:26PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.12 to a high of $6.65. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $6.25 on volume of 14.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today
at The Street - Tue Aug 26, 11:36AM CDT
Ariad Pharmaceuticals (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune (ITMN) has led the biotech sector higher.

5 Stocks Insiders Love Right Now
at The Street - Thu Aug 21, 1:11PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.

Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.90% Rise
Comtex SmarTrend(R) - Tue Aug 12, 5:00PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.48 to a high of $5.79. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $5.63 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

ARIAD Falls on Wider-than-Expected Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:21AM CDT
ARIAD (ARIA) reported a loss of 30 cents per share in the second quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 27 cents.

11.6% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Fri Aug 08, 10:00AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 1 month, Ariad Pharmaceuticals has returned 11.62% as of today's recent price of $5.36.

ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Aug 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.

Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 3:45PM CDT
GW Pharmaceuticals (GWPH) is scheduled to report third-quarter fiscal 2014 results on Aug 6.

Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:48AM CDT
Ariad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.

ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
Business Wire - Tue Aug 05, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig(R) (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.

The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq

RTX-Free Report).

Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:

3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.

3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CSS Revamps Identity, Emphasizing Senior Living Tech

CSS Takes a Bold Step with a Fresh Brand Identity Every now and then, you see a company shake off the old coat and put on a polished new one. That's what CSS is doing with its updated brand, staking its claim as a heavyweight tech player in the senior living sector. No small feat, given the challenges stacked against these aging communities—tasked with keeping...

G-STAR & Wu-Tang Clan Unleash Denim Fusion

Denim and Old-School Beats: A Fresh Partnership Just when you think fashion collaborations have run their course, along comes something worth the buzz. This fall, G-STAR, the edgy Dutch denim frontrunner, and the legendary hip-hop collective of Wu-Tang Clan are shaking up the apparel scene, blending raw denim with raw rap. It's a multi-year collaboration that doesn't slap...

Postal Connections Expands with New Hillsboro Opening

Expanding Horizons in Hillsboro In the world of postal and office services, Annex Brands, Inc. is making headlines by launching yet another Postal Connections spot, this time planting its flag in the tech-centric town of Hillsboro, Oregon. Spearheaded by Jason Rautenkranz, this expansion is more than just another dot on a map—it's a strategic push into one of the...

Lumicell Expands LumiSystem in Breast Cancer Surgery

Innovation in Breast Cancer Surgery: A Real-World Game Changer? You’ve got your flashlight guiding a scared child through the dark, and in the healthcare world, Lumicell is promising to do just that for surgeons navigating the tricky maze of breast cancer surgery. Their LumiSystem is making waves in breast-conserving surgery—new kid on the block with a real chance at...

MSP360 Unveils Free Proxmox Backup: A Game Changer?

Backing Up: New Paths for Proxmox Users Ever get that feeling of uncovering something truly worth its weight in gold? That's what MSP360 just dropped on us, with their new backup solution for Proxmox that won’t cost you a dime upfront. They're calling it the Community Edition, and it’s not only free, but it comes with all the bells and whistles for protecting those...

Alcott HR's Sales Strategy Gets a Boost with New Hire

Alcott HR Ramps Up Sales Firepower Now here's something fresh from the world of human resources outsourcing—Alcott HR has grabbed a new ace for their sales team. Eldin Radoncic is the name you'll want to remember, folks, because he's diving headfirst into the Director of Sales seat at this IRS Certified and ESAC Accredited player based out in good old Farmingdale, New...

RxWellness Hits Inc. 5000—Four Straight Wins Impress

RxWellness Spine & Health Continues to Impress Well, not many companies can boast about snagging a spot on the Inc. 5000 list four years in a row, but here we are with RxWellness Spine & Health doing just that. Sitting pretty at No. 1,230 nationally—and that's no small feat—these folks are making waves in the healthcare industry. Securing the No. 135 spot in...

Orthopedic Expert Highlighting Midwest Pain Access Gaps

Over in the vast sprawl of rolling plains and prairie winds, folks in the Upper Midwest are grappling with an ironic reality. As technological advancements blaze trails, people suffering from vertebrogenic pain are finding themselves up against a wall of limited access to specialized care. We’ve got Dr. James T. Brunz, the man of the hour, one of only about 15 Intracept...

TWP & Commbi Unveil Exclusive Pony Clog Collaboration

A Fusion of Fashion and Functionality Walk down the streets of New York or hustle your way through an airport without worrying about your footwear weighing you down. That's the promise coming from the fresh alliance between TWP and Commbi with their new Pony Clog Collaboration. A blend of high fashion and everyday utility, these clogs aren't just keeping up with the...

Perk's U.S. Expansion: A Bold Move in Spend Control

Perk Aims for U.S. Growth: Will It Pay Off? Amidst the cacophony of market chatter, Perk's announcement to bring its spend platform stateside is echoing louder than usual. This move is not just another step in its expansion but rather a leap considering the competition and market needs. In Europe, where they've already captured a chunk of the market with their Travel and...